

# Syndax



Reimagining Cancer Treatment

## J.P. Morgan 44th Annual Healthcare Conference


January 12, 2026



# Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, the progress of regulatory submissions and approvals and subsequent commercialization and the potential use of Syndax's product candidates to treat various cancer indications and fibrotic diseases, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical site activation rates or clinical trial enrollment rates that are lower than expected; changes in expected or existing competition; the impact of macroeconomic conditions (the Russia-Ukraine war, inflation, among others) on Syndax's business and that of the third parties on which Syndax depends, including delaying or otherwise disrupting Syndax's clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

# Syndax is a commercial-stage oncology company with a track record of execution and two approved medicines with multi-billion-dollar opportunities



Two first- & best-in-class drugs with opportunities for further expansion



Three FDA approvals  
+  
Strong Revuforj and Niktimvo launches



On the road to profitability, with growing revenue, stable expense outlook, and \$394M preliminary YE25 cash\*

 **Revuforj**<sup>®</sup>  
(revumenib) tablets  
25 mg • 110 mg • 160 mg

**\$5B+ TAM**  
R/R & 1L acute leukemia

 **Niktimvo**<sup>™</sup>  
(axatilimab-csfr)

**\$5B+ TAM**  
R/R & 1L cGVHD



# REVUFORJ IS FDA-APPROVED FOR MULTIPLE PATIENT SUBTYPES



NOW APPROVED FOR A SECOND INDICATION

**ONE MENIN INHIBITOR**  **MULTIPLE INDICATIONS**

As the one menin inhibitor with two FDA-approved indications, Revuforj has the power to target multiple acute leukemia subtypes\*




First and only menin inhibitor approved in adults & children  $\geq 1$  year of age with:

R/R acute leukemia with KMT2A translocation


R/R AML with NPM1 mutation

# Current Revuforj indications unlock \$2B+ TAM in R/R acute leukemia



With the *largest addressable population* and anticipated duration of therapy, Revuforj is poised to become the largest targeted AML therapy

## Addressable AML population



Comprehensive clinical development program underway to unlock \$5B+ TAM across acute leukemia Tx continuum

# Revuforj is positioned for long-term success with a best-in-class profile and first-mover advantage

## BEST-IN-CLASS PROFILE



- Unmatched efficacy across multiple patient subtypes
- Well-tolerated with individualized dosing
- Can be used concomitantly with other commonly used drugs, including gastric acid reducing agents

## FIRST-MOVER ADVANTAGE



- Robust and growing prescriber base with >1 year of commercial product experience
- Excellent market access and reimbursement
- Trusted partner to HCPs, with a track record of delivering for patients

# Strong Revuforj launch underscores exceptional product profile and execution

 **Revuforj**  
(revumenib) tablets  
25 mg • 110 mg • 160 mg

**~\$44M**

Preliminary 4Q25  
net revenue\*

↑  
**~38% q/q growth**

**~1,150**

4Q25 total  
prescriptions (TRx)

↑  
**~35% q/q growth**

**~\$125M**

Preliminary full year  
2025 net revenue\*

Growth driven by  
**strong patient demand**

**Continued acceleration  
in demand** following  
approval in R/R NPM1m

**1<sup>st</sup> year results surpass launch benchmarks set by other AML therapies**

# Evolving clinical practice will drive continued Revuforj growth in 2026

1

Movement to earlier lines of Tx and growing combination use

↑ Tx durations

2

Building transplant rate in KMT2Ar and usage post-transplant


↑ Tx durations



3

Growing adoption in R/R NPM1m AML

↑ patient population

# Syndax is positioned to be first to the 1L with a menin inhibitor, building on a long history of ‘firsts’ with Revuforj



-  Completed milestones
-  Anticipated milestones

# Advancing the broadest data generation plan to rapidly deliver practice-changing Revuforj evidence and support global registrations in acute leukemia

## FRONTLINE

## MAINTENANCE & MRD RELAPSE

## RELAPSED / REFRACTORY

### INELIGIBLE FOR IC ('UNFIT')

### ELIGIBLE FOR IC ('FIT')

#### BEAT AML

Rev + ven/aza in NPM1m & KMT2Ar

#### SNDX-708

Rev + IC in NPM1m, KMT2Ar, NUP98r

#### Post-HSCT Maintenance

#### AUGMENT-102

Rev + FLA in KMT2Ar, NPM1m, NUP98r

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### NCI collaboration

Rev + IC in NPM1m & KMT2Ar

#### INTERCEPT

MRD relapse

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### EVOLVE-2

Rev + ven/aza in NPM1m & KMT2Ar

#### REVEAL-ND NPM1

Rev + IC in NPM1m

#### Break Through Cancer

MRD relapse

#### AUGMENT-101

Rev in KMT2Ar & NPM1m

#### RAVEN

Rev + ven/aza in KMT2Ar

Generating a robust and differentiated body of evidence supporting Revuforj through a strategic combination of company-sponsored and collaborative trials

# Advancing the broadest data generation plan to rapidly deliver practice-changing Revuforj evidence and support global registrations in acute leukemia

## FRONTLINE

## MAINTENANCE & MRD RELAPSE

## RELAPSED / REFRACTORY

### INELIGIBLE FOR IC ('UNFIT')

#### BEAT AML

Rev + ven/aza in NPM1m & KMT2Ar

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### EVOLVE-2

Rev + ven/aza in NPM1m & KMT2Ar

### ELIGIBLE FOR IC ('FIT')

#### SNDX-708

Rev + IC in NPM1m, KMT2Ar, NUP98r

#### NCI collaboration

Rev + IC in NPM1m & KMT2Ar

#### REVEAL-ND NPM1

Rev + IC in NPM1m

#### RAVEN

Rev + ven/aza in KMT2Ar

#### Post-HSCT Maintenance

#### INTERCEPT

MRD relapse

#### Break Through Cancer

MRD relapse

#### AUGMENT-102

Rev + FLA in KMT2Ar, NPM1m, NUP98r

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### AUGMENT-101

Rev in KMT2Ar & NPM1m

- ✓ AUGMENT-101 supported FDA approvals
- ✓ Combo trials provide practice-informing data

# Advancing the broadest data generation plan to rapidly deliver practice-changing Revuforj evidence and support global registrations in acute leukemia

## FRONTLINE

## MAINTENANCE & MRD RELAPSE

## RELAPSED / REFRACTORY

### INELIGIBLE FOR IC ('UNFIT')

#### BEAT AML

Rev + ven/aza in NPM1m & KMT2Ar

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### EVOLVE-2

Rev + ven/aza in NPM1m & KMT2Ar

### ELIGIBLE FOR IC ('FIT')

#### SNDX-708

Rev + IC in NPM1m, KMT2Ar, NUP98r

#### NCI collaboration

Rev + IC in NPM1m & KMT2Ar

#### REVEAL-ND NPM1

Rev + IC in NPM1m

#### RAVEN

Rev + ven/aza in KMT2Ar

#### Post-HSCT Maintenance

#### INTERCEPT

MRD relapse

#### Break Through Cancer

MRD relapse

#### AUGMENT-102

Rev + FLA in KMT2Ar, NPM1m, NUP98r

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### AUGMENT-101

Rev in KMT2Ar & NPM1m

- ✓ Robust data generation plan underway in collaboration with leading cancer centers

# Advancing the broadest data generation plan to rapidly deliver practice-changing Revuforj evidence and support global registrations in acute leukemia

## FRONTLINE

## MAINTENANCE & MRD RELAPSE

## RELAPSED / REFRACTORY

### INELIGIBLE FOR IC ('UNFIT')

#### BEAT AML

Rev + ven/aza in NPM1m & KMT2Ar

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### EVOLVE-2

Rev + ven/aza in NPM1m & KMT2Ar

### ELIGIBLE FOR IC ('FIT')

#### SNDX-708

Rev + IC in NPM1m, KMT2Ar, NUP98r

#### NCI collaboration

Rev + IC in NPM1m & KMT2Ar

#### REVEAL-ND NPM1

Rev + IC in NPM1m

#### RAVEN

Rev + ven/aza in KMT2Ar

#### Post-HSCT Maintenance

#### INTERCEPT

MRD relapse

#### Break Through Cancer

MRD relapse

#### AUGMENT-102

Rev + FLA in KMT2Ar, NPM1m, NUP98r

#### SAVE

Rev + ven/HMA in NPM1m, KMT2Ar, NUP98r

#### AUGMENT-101

Rev in KMT2Ar & NPM1m

- ✓ Encouraging data from ongoing combo trials
- ✓ EVOLVE-2 and REVEAL trials underway with dual primary endpoints to support potential for accelerated and full approval
- ✓ Innovative RAVEN trial planned in fit KMT2Ar



# Niktimvo is poised to deliver on the promise of CSF-1R inhibition in cGVHD and beyond




First and only CSF-1R-blocking antibody  
FDA approved in  $\geq 3$ L cGVHD

Novel MoA in cGVHD to address  
inflammation and fibrosis

Trials underway in 1L cGVHD  
& IPF to further unlock multi-  
billion-dollar opportunity

# Initial Niktimvo indication represents a \$2B U.S. market opportunity, with substantial opportunities for label and geographic expansion



# Strong Niktimvo results highlight the importance of this novel medicine to patients and Syndax



**\$56M**

Preliminary 4Q25 net revenue\*

↑ *22% q/q growth*

**\$152M**

Preliminary full year 2025 net revenue\*

The Company expects its share of the Niktimvo net profit to equal ~25-30% of Niktimvo net revenue

Niktimvo sales annualizing at >\$200M within first launch year

Contribution to Syndax expected to materially grow over time

# Multiple drivers for continued Nektimvo growth in 2026

1

Rapid adoption in 4L  
with growing usage  
in 3L cGVHD

2


Patients are staying  
on therapy with  
potential for long  
treatment durations

3

Solid prescriber base  
(~90% of U.S. BMT  
centers have ordered)

# Robust Niktimvo clinical development plan underway to drive future growth

## Chronic graft-versus-host disease (cGVHD)



## Idiopathic pulmonary fibrosis (IPF)

**MAXPIRe Ph 2 trial**  
Axa with SOC

- Development in IPF supported by strong preclinical and clinical evidence
- 26-week, randomized, double-blind, placebo-controlled, multi-center trial; primary endpoint:  $\Delta$  FVC
- **Topline data anticipated 2H26**

# 2026 Priorities and Anticipated Milestones

# Proven execution supports continued focus on revenue growth, pipeline development, and data generation

## 2025 Key Accomplishments

- ✓ Executed two strong product launches
- ✓ Expanded Revuforj into 2<sup>nd</sup> indication
- ✓ Initiated 1<sup>st</sup> pivotal 1L trial of amenin inhibitor
- ✓ Presented first RWE for amenin inhibitor
- ✓ Initiated managed access program, expanding access to Revuforj in certain OUS regions

## 2026 Anticipated Milestones

- Report topline Ph 2 axatilimab data in IPF in 2H26
- Advance global enrollment in pivotal 1L trials of revumenib
- Continue to publish & present industry leading clinical data, including revumenib data from 1L and maintenance setting
- Initiate RAVEN 1L trial of revumenib in fit KMT2Ar
- Initiate a program to generate proof-of-principle clinical data with revumenib in myelofibrosis (MF)

